Researcher Profile

Darlene G. Gibbon, MD

Chief, Gynecologic Oncology at the Rutgers Cancer Institute of New Jersey
Associate Professor of Obstetrics, Gynecology and Reproductive Sciences, Division of Obstetrics and Gynecology
Robert Wood Johnson Medical School
Rutgers, The State University of New Jersey

Rutgers Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08901-1914

Phone: (732) 235-7258
Email: gibbonda@cinj.rutgers.edu

Assistant: Marilou Benenati
(732) 235-7258
Email: benenama@cinj.rutgers.edu

Research Program Alignments

Membership Type: Associate - CCSG


Research Interests

  • Ovarian Cancer
  • Gynecologic Cancers
  • Phase I Research Trials
  • Women's Health

Selected Publications

Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, DeMario M, Kurzrock R, and Wheler JJ. A Phase I Study of RO4929097, a γ-Secretase Inhibitor of Notch Signaling, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors. J Clin Oncol. 2012 Jul 1;30(19):2348-53.

Rodriguez-Rodriguez L, Sancho-Torres I, Mesonero C, Gibbon DG, Shih WJ, Zotalis G. The CD44 Receptor is a Molecular Predictor of Survival in Ovarian Cancer. Med Oncol. 2003;20(1)

Rodriguez-Rodriguez L, Sancho-Torres I, Bostock E, Gibbon DG, Mesonero C, Zotalis G, Malka E, and Shih W. CD44 Receptor is a Molecular Predictor of Survival in Ovarian Cancer.  Medical Oncol 2001;80:324.

Sancho-Torres I, Mesonero C, Miller Watelet L, Gibbon DG and Rodriguez-Rodriguez L. Clear Cell Carcinoma of the Ovary: Characterization of Its CD44 Isoform Repertoire. Gynecol Oncol. 2000;79:187-195.

Rodriguez-Rodriguez L, Sancho-Torres I, Gibbon DG, Miller Watelet L and Mesonero C. CD44-9v and CD44-10v are Potential Molecular Markers for Squamous Cell Carcinoma of the Vulva. J Gynecol Invest. 2000;7:69-76.

Rodriguez-Rodriguez L, Sancho-Torres I, Waterlet LM, Gibbon DG, Comerci JT and Mesonero C. Prognostic Value of CD44 Expression in Invasive Squamous Cell Carcinoma of the Vulva. Gyn Oncol. 1999;(75):34-40

Rodriguez-Rodriguez L, Sancho-Torres I, Leakey P, Gibbon DG, Comerci JT, Ludlow J and Mesonero C. CD44 Slice Variant Expression in Clear Cell Carcinoma of the Ovary. Gynecol Oncol. 1998;71:223-229.

Remy JC, Ponda B, Fruchter RG, Maiman M, Arrastia CD and Gibbon DG. Extragenital Malignant Mixed Mullerian Tumor. Int J Gynecol Cancer. 1997;7:325-28.

Matthews RP, Hutchinson-Colas J, Maiman M, Fruchter RG, Gates EJ, Gibbon DG, Remy JC and Sedlis A. Papillary Serous and Clear Cell Type Lead to Poor Prognosis of Endometrial Carcinoma in Black Women. Gynecol Oncol. 1997;65:206-12.

Gemignani M, Maiman M, Fruchter RG, Arrastia CD, Gibbon DG and Ellison T. CD4 Lmphocytes in Women with Invasive and Pre-invasive Cervical Neoplasia. Gynecol Oncol. 1995;59:364-9.

Serur E, Fruchter RG, Maiman M, McGuire J, Arrastia CD and Gibbon DG. Age, Substance Abuse and Survival in Cervical Carcinoma. Cancer. 1995;75:2530-8.

Goldberg G, Gibbon DG, Smith HO, DeVictoria C, Runowicz CD and Burns ER. Clinical Impact of Chemotherapy Induced Thrombocytopenia in Patients with Gynecologic Cancer. J Clin Oncol. 1994;12:2317-20.

The content for this Research Profile is maintained by Paul Novembre (novembre@cinj.rutgers.edu)